Section Arrow
Quote
BLSM.NASDAQ
- BlossomHill Therapeutics Inc
Quotes are at least 15-min delayed:2026/08/07 12:55 EDT
Regular Hours
Last
 15.64
-- (--)
Day High 
16.05 
Prev. Close
-- 
1-M High
-- 
Volume 
734.00K 
Bid
15.6
Ask
15.65
Day Low
15.55 
Open
15.75 
1-M Low
-- 
Market Cap 
-- 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA -- 
20-SMA -- 
50-SMA -- 
52-W High -- 
52-W Low -- 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
--/--
Enterprise Value
--
Balance Sheet
Book Value Per Share
N/A
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
--
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CELZCreative Medical Technology Holdings1.325+0.175+15.22%-- 
IOVAIovance Biotherapeutics5.985-0.225-3.62%-- 
ARDXArdelyx4.005-0.865-17.76%-- 
ENSCEnsysce Biosciences0.50355-0.02075-3.96%-- 
REPLReplimune Group12.25-0.61-4.74%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.